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Founder mutationIsolated complex I deﬁciency is a frequent cause of respiratory chain defects in childhood. In this study, we
report our systematic approach with blue native PAGE (BN-PAGE) to study mitochondrial respiratory chain
assembly in skin ﬁbroblasts from patients with Leigh syndrome and CI deﬁciency. We describe ﬁve new
NDUFS4 patients with a similar and constant abnormal BN-PAGE proﬁle and present a meta-analysis of the
literature. All NDUFS4 mutations that have been tested with BN-PAGE result in a constant and similar abnor-
mal assembly proﬁle with a complete loss of the fully assembled complex I usually due to a truncated protein
and the loss of its canonical cAMP dependent protein kinase phosphorylation consensus site. We also report
the association of abnormal brain MRI images with this characteristic BN-PAGE proﬁle as the hallmarks of
NDUFS4 mutations and the ﬁrst founder NDUFS4 mutations in the North-African population.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Isolated complex I (CI) deﬁciency is the most frequent cause of re-
spiratory chain defects in childhood [1]. It accounts for various clinical
presentations including Leigh syndrome associated with hypotonia,
developmental delay, visual impairment, seizures or cardiomyopathy
[2]. Mammalian CI (NADH:ubiquinone oxidoreductase; EC 1.6.5.3) is
the largest component of the respiratory chain (RC) (~1MDa in
size) and comprises seven core subunits encoded by mitochondrial
DNA (mtDNA), 38 nuclearly-encoded core subunits and many assem-
bly factors [1–3]. Disease causing mutations have been identiﬁed in
22 core subunits including ﬁfteen nuclear genes (NDUFS1–4,
NDUFS6–8, NDUFV1–2, NDUFA1–2 and NDUFA9–A12) and seven
mtDNA genes but also in nine assembly factors (NDUFAF1–4,olyacrylamide gel electropho-
chondrial DNA, RC, respiratory
lation enzymes; PND, prenatal
des, Département de Génétique,
France. Tel.:+33 1 44 49 51 64;
Lebre).
l rights reserved.C20orf7, Ecsit, NUBPL, C8orf38 and ACAD9) [3–6]. In addition, an
uncharacterized protein (FOXRED1) has been recently identiﬁed as
causing CI deﬁciency [7].
The subunit composition and general topology of CI has been de-
ﬁned. The CI enzyme has an L-shaped structure consisting of a hydro-
phobic membrane arm and a peripheral arm that protrudes into the
mitochondrial matrix [8]. Newly imported CI subunits, encoded by
the nuclear genome, assemble in coordination with the highly hydro-
phobic subunits encoded by mtDNA. CI further assembles into higher-
ordered supercomplexes with RC complexes CIII and CIV [9]. The
supercomplexes might serve to reduce the diffusion distance of the
substrates, to improve electron transfer, to decrease the reactive oxy-
gen species formation and to stabilize the individual complexes [10].
A consensus model for holo-enzyme CI assembly in human was
recently suggested with a set of smaller assembly intermediates iden-
tiﬁed via blue native polyacrylamide gel electrophoresis (BN-PAGE)
[3]. The involvement of CI proteins was deﬁned at the different stages
of the assembly process, trying to explain how protein defects disrupt
CI assembly and ultimately lead to mitochondrial disease. In addition
to fully assembled CI (~1 MDa), six to ten putative assembly interme-
diates with lower molecular weights have been identiﬁed [3,11]. Bio-
chemically, mutations in mitochondrial or nuclear genes involved in
CI structure or assembly may result in a decrease or loss of the
1063Z. Assouline et al. / Biochimica et Biophysica Acta 1822 (2012) 1062–10691 MDa band and accumulation of assembly intermediates or break-
down products [12,13].
Mutations in NDUFS4, NDUFV1 and NDUFS6 lead to decreased
levels of assembled holo-enzyme-CI with the accumulation of CI
~830 kilodaltons (kDa) sub complex, which indicates a disturbance
in the assembly and/or stability of CI [12,14–17]. The NDUFS4 protein,
encoded by the human equivalent of the bovine AQDQ gene (or
18 kDa), is 175 amino acids long, and its calculated molecular mass
is 23 kDa. NDUFS4 amino acid sequence contains a mitochondrial sig-
nal peptide (AA 1–42), which is cleaved after import into the mito-
chondria. The protein is phosphorylated by the cAMP-dependent
protein kinase A (PKA) at the serine Ser173 of the C-terminal RVSTK
consensus site (AA 171–175) [18]. Activation of the cAMP cascade
and NDUFS4 protein phosphorylation could have a role in the assem-
bly of the functional CI [19] and promotes its import/maturation in
mitochondria [20]. CI assembly studies of patient ﬁbroblasts showed
that the NDUFS4 subunit is inserted in the complex at the late stage
of the assembly process [12,14,15]. It has also been associated with
activation of the NADH–ubiquinone oxidoreductase activity of the
complex and could promote exchange of pre-existing, possibly func-
tionally impaired, NDUFS4 subunits in the complex with the newly
synthesized protein [12]. Finally, it has been apparently involved in
prevention of accumulation of oxygen free radicals [19]. Phosphoryla-
tion of the NDUFS4 mature protein, once imported in mitochondria,
can be modulated by the PKA and the protein phosphatase present
in the mitochondrial matrix [18].
No clear genotype–phenotype correlation or correlation between
genotype and BN-PAGE proﬁle has been hitherto reported. During
the last four years, we collected ﬁbroblasts of patients with CI deﬁ-
ciency in muscle and/or ﬁbroblasts, and analyzed RC assembly with
BN-PAGE. This study allowed us to identify a constant abnormal BN-
PAGE proﬁle in our NDUFS4 patients. Here, we describe the clinical,
radiological, biochemical, and genetic features of ﬁve new NDUFS4
patients and compared them with the phenotype of NDUFS4 patients
reported in the literature. This meta-analysis of the literature con-
ﬁrmed that this same abnormal BN-PAGE proﬁle was always ob-
served in all NDUFS4 patients described and then appears to be the
hallmark to directly search for NDUFS4mutations. In addition, we re-
port the ﬁrst NDUFS4 founder mutations in the North-African
population.
2. Materials and methods
2.1. Patients
Written informed consent was previously obtained from all pa-
tients participating in the study. The new NDUFS4 patients (P1 to
P5) are described in Fig. 2A and Table 1. Patient P1 was brieﬂy evo-
cated [21] but never described. Patients P6 and P7 were previously
described [22,23].
2.2. Biochemical and molecular analysis
Spectrophotometric assays of respiratory chain (RC) enzymes
were performed on muscle, and ﬁbroblasts as described [24].
For blue native-polyacrylamide gel electrophoresis (BN-PAGE),
mitochondria and the oxidative phosphorylation (OXPHOS) com-
plexes from patient and control ﬁbroblasts were isolated using 2%
(w/v) digitonin and analyzed as described [25]. Solubilized OXPHOS
proteins (15 μg) were loaded on a 4–16% acrylamide non-
denaturing gradient gel (Invitrogen). After electrophoresis, gels
were transferred to a PVDFmembrane (GE-Healthcare). Immunoblot-
ting was performed with monoclonal antibodies raised against
GRIM19 (complex I subunit), 70 kDa (complex II subunit), core 2
(complex III subunit), COX1 (complex IV subunit) and beta complex
V subunit (Mitosciences). Secondary antibody detection wasperformed using peroxidase-conjugated anti-mouse IgGs (Abcam).
The signal was generated using ECL (Pierce, Rockford, USA).
Blood samples were obtained from the probands and their par-
ents, and genomic DNA was isolated from EDTA-anticoagulated
blood by standard procedures. Ampliﬁcation of the coding sequences
of the NDUFS4 gene was performed on genomic DNA. PCR fragments
were puriﬁed by ExoSapIT (Amersham Pharmacia Biotech, Bucking-
hamshire, UK) and directly sequenced using the Prism™ Ready Reac-
tion Sequencing Kit (PE Applied Biosystems, Foster City, CA, USA)
after Sephadex puriﬁcation with an automatic sequencer (ABI 3500,
PE Applied Biosystems). GenBank sequence NM_002495.2 was used
as the NDUFS4 reference sequence. DNA mutation numbering is
based on the cDNA sequence. HGVS nomenclature was checked
with Mutalyzer 2.0 software. Analyses of the wild-type and mutant
sequences were performed using websites predicting mutation ef-
fects (swissprot number O43181, Polyphen http://genetics.bwh.
harvard.edu/pph/, BDGP: http://www.fruitﬂy.org/seq_tools/splice.
html, SSF: http://www.umd.be/SSF). SNP genotyping using the Gene-
Chip Human Mapping 250K Array (Affymetrix) was performed for
patient 5. Microsatellite markers ﬂanking the NDUFS4 locus on chro-
mosome 5 were tested in parents and affected siblings.
3. Results
3.1. BN-PAGE analysis
We studied the OXPHOS complexes using BN-PAGE analysis in
cultured skin ﬁbroblasts of patients with isolated CI deﬁciency. The
gels were subsequently blotted and incubated with ﬁve antibodies
speciﬁc of each RC complex. A same BN-PAGE proﬁle was identiﬁed
for six patients, with the complete absence of the fully assembled CI
(~1 MDa) in contrast to control cells, and the accumulation of a late
stage assembly intermediate of ~830 kDa after incubation with
GRIM-19 antibody (Fig. 1). Other RC complexes including complex II
remained normal as compared to controls.
3.2. Clinical, radiological and biological features
The pedigree of the families and the clinical, radiological and bio-
logical features of the ﬁve new NDUFS4 patients (patients P1 to P5)
are summarized in Table 1. Brain Magnetic Resonance Imaging
(MRI) images were available for three patients (P1/P4/P7) [26] and
data not shown). Abnormal brain images were observed in all three
patients. Bilateral and symmetric brainstem T2 hyperintensities
were constantly observed and were associated with putamen or pal-
lidal signal abnormalities (in P1 and P7, respectively). Magnetic reso-
nance spectroscopy (MRS) was performed for patient P1, voxels were
placed over the brain lesions and a lactate peak was consistently
found. RC enzyme measurements showed low level of CI residual ac-
tivity in muscle and ﬁbroblasts of patients compared to control (4 to
35% of residual activity in muscle and 34 to 76% in ﬁbroblasts)
(Table 1). Complex III activity was normal (92 to 107% of residual ac-
tivity in muscle and 87 to 160% in ﬁbroblasts) (Table 1). A speciﬁc
pattern of clinical symptoms was not identiﬁed for these ﬁve patients
and NDUFS4 gene was suspected to be the disease-causing gene based
mainly on the brain images and the abnormal BN-PAGE proﬁle
[15,17].
3.3. NDUFS4 sequencing
New mutations are presented in Fig. 2B–C and all NDUFS4 muta-
tions are compiled in Table 3.
The absence of PCR ampliﬁcation ofNDUFS4 exons 3 to 5 onpatient P1
genomic DNA prompted us to perform comparative genomic hybridiza-
tion (CGH) on high resolution oligonucleotides microarray (Affymetrix
CytogeneticsWhole-Genome 2.7MArray). This showed that P1 harbored
Table 1
Clinical, radiological and biological features of NDUFS4 patients. For patients P1 to P5, respiratory chain (RC) complex I (CI) and complex III (CIII) residual activities were normalized to citrate synthase activity. RC was considered as deﬁcient
when residual activity of a complex was fewer than 80%.
Reference This study Benit et al.
[22]
Leshinsky-
Silver et al.
[23]
van den Heuvel et al.
[29], Scacco et al.
[33], Ugalde et al.
[14], Vogel et al. [17]
Budde et al. [27],
Scacco et al. [33],
Ugalde et al. [14],
Vogel et al. [17]
Petruzzella et
al. [30], Scacco
et al. [33], Iuso
et al. [32]
Budde et
al. [31]
Anderson
et al. [28]
Calvo et al.
[7]
Total
Patients from this study P1 P2 P3 P4 P5 P6 P7
Number of patients
(number of families)
1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 2 (1) 1 (1) 1 (1) 2 (2) 1 (1) 1 (1) 3 (1) 2 (2) 18 (15 families)
Gender
(F female/M male)
1M 1F 1F 1M 1F 2F 1M 1M 1F/1M 1F 1F 1F/2M na 9F/7M
Origin France Morocco Algeria Morocco Morocco Morocco Ashkenazi-
Sephardic
Jewish
Caucasian na na Turkey Ashkenazi
Jewish
Caucasian-
Indian, na
Age at onset 4 months 5 days 3 months 22 months 3 months 10 weeks/
3.5 months
8 months 8 months 1 weeks/7 weeks 2 weeks 4 months 3.5 months/
5 months/
6 months
3 months/
4 months
5days–
22 months
(mean
4.5 months)
Age at death 6 months na 6 months 24 months 4.5 months 4 months /
na
27.5 months 16 months 3 months/
3 months
7 months 8 months 6 months/
10 months/
10 months
na /
4.5 months
3months–
27.5months
(mean
9.3 months)
Hypotonia 1/1 1/1 1/1 1/1 1/1 2/2 1/1 1/1 2/2 1/1 1/1 3/3 2/2 18/18
Intra-uterine growth
retardation (IUGR)
1/1 0/1 1/1 0/1 1/1 1/2 0/1 0/1 na 0/1 0/1 2/3 na 6/14
Post-natal growth
retardation
1/1 0/1 1/1 0/1 1/1 1/2 0/1 0/1 na na 0/1 2/2 na 6/12
Failure to thrive na na na na 1/1 na na 1/1 2/2 1/1 1/1 1/1 na 7/7
Psychomotor retardation
or regression
na na 1/1 1/1 1/1 1/1 1/1 1/1 0/2 1/1 0/1 1/1 1/1 9/12
Microcephaly 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 1/2 0/1 0/1 na na 1/12
Absence of eye contact 1/1 na na 1/1 1/1 1/1 na na 2/2 na na na 2/2 8/8
Abnormal vision
(nystagmus,strabism,
ptosis, ophtalmoplegia)
1/1 na 1/1 1/1 na na 1/1 na na na na 2/2 1/1 7/7
Abnormal AEP na na na na na na na na 1/1 na na na na 1/1
Apnoeic episodes,
Bradypnea, cyanosis
1/1 na 1/1 1/1 1/1 1/1 na 1/1 0/2 1/1 1/1 1/1 1/1 10/12
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Feeding problems,
gastrostomy
1/1 1/1 1/1 na 1/1 na na na 1/1 na na 2/2 na 7/7
Vomiting na na na 0/1 0/1 na na 1/1 0/2 1/1 0/1 na na 2/7
Epilepsy / Seizures na na 1/1 na 0/1 na na 1/1 0/2 1/1 na na 1/1 4/7
Abnormal EEG 1/1 0/1 1/1 1/1 1/1 na 0/1 na 0/1 na 1/1 1/1 na 6/9
Hypertrophic
cardiomyopathy
1/1 0/1 1/1 0/1 0/1 0/1 na 0/1 1/2 1/1 na 1/1 na 5/11
Pyramidal syndrome 1/1 na na 1/1 1/1 na 1/1 na na na na na na 4/4
Depressed tendon
reﬂexes
na na na 1/1 0/1 1/1 0/1 1/1 na na na na na 3/5
Hepatomegaly 1/1 na 1/1 0/1 1/1 0/1 0/1 na 1/1 na na na na 4/7
Death caused by
cardiorespiratory failure
1/1 na na 1/1 1/1 1/1 1/1 1/1 1/1 1/1 na na na 8/8
Brain images (CT-Scan/MRI)
Abnormal brain images 1/1 na na 1/1 1/1 2/2 1/1 1/1 2/2 1/1 1/1 2/2 2/2 15/15
Brainstem : signal
abnormalities or
involvement
1/1 na na 1/1 1/1 2/2 1/1 1/1 1/2 na 1/1 2/2 na 11/12
Basal ganglia
signal abnormalities
1/1 na na 0/1 1/1 1/2 1/1 1/1 2/2 1/1 1/1 0/1 na 9/12
Cortical atrophy 0/1 na na 0/1 0/1 1/2 0/1 1/1 0/2 0/1 1/1 0/1 na 3/12
Muscle histology
Ragged red ﬁbers na na na 0/1 na na 0/1 0/1 1/1 0/1 0/1 0/1 na 1/7
Lipids accumulation na na na 1/1 na na 0/1 na 1/1 1/1 1/1 na na 4/5
Biochemical investigations
Lactate elevation
in Plasma
1/1 1/1 1/1 na 1/1 2/2 na 0/1 2/2 1/1 1/1 3/3 2/2 15/16
Lactate elevation in CSF 1/1 na 1/1 na 1/1 1/1 na 0/1 2/2 1/1 1/1 1/1 2/2 11/12
RC (% of residual activity)
CI deﬁciency in muscle 1/1 (4%) 1/1 (6%) 1/1
(35%)
1/1 (33%) 1/1 (na) 1/1 (48%) 1/1 (54%) 1/1 (na) 2/2 (14–22%) 1/1 (35%) 1/1
(10%)
1/1 (47%) 2/2 (3–8%) 15/15 (3–54%,
mean 24.5%)
CI deﬁciency in
skin ﬁbroblasts
1/1
(34%)
1/1
(47%)
1/1
(69%)
1/1 (76%) na na 0/1 (na) 1/1 (75%) 2/2 (47–60%) 1/1 (16%) 1/1
(30%)
na 2/2 (15–
16%)
10/11 (15–85%,
mean 45%)
CIII deﬁciency in muscle 0/1
(107%)
0/1
(115%)
0/1
(93%)
0/1 (92%) na 0/1 (197%) na na 1/1 (57%–na) 0/1 (100%) 0/1
(91%)
na 0/2 (80–
117%)
1/10 (57–197%,
mean 105%)
CIII deﬁciency
in skin ﬁbroblasts
0/1
(87%)
0/1
(130%)
0/1
(160%)
0/1 (97%) na na na 0/1 (96%) 1/2 (67–87%) 0/1 (100%) 0/1
(88%)
na 0/2 (138–
139%)
1/11 (67–160%,
mean 108%)
na: data not available; CSF cerebrospinal ﬂuid; VEP visual evoked potentials; AEP auditory evoked potentials.
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Mb which proximal and distal breakpoints mapped within the probes
C-0ZSCY (52,921,361) and C-0ZSEN (53,009,414) encompassing
NDUFS4 exons 3 to 5 (c.178_528del, p.Asp60_Lys175del — Fig. 2B).
Probes S-2J7KV (52,928,392) and C-0ZSEK (52,993,587) were not
hybridized. DNA samples of parents of patient P1 were not
available.
Patients P2, P5 and P6 carried a known homozygous substitution
c.99-1G>A (p.Ser34IlefsX5) in intron 1 [22]. The parents of patients
P2 and P6 were heterozygous for the mutation. Fibroblasts of patient
P5 were not available for BN-PAGE study. A genome-wide linkage
analysis using Affymetrix gene-chip SNP 250K array detected 3 ho-
mozygosity regions for P5 ranging from 18 to 22 Mb encompassing
4 genes encoding mitochondrial proteins known as components of
complex CI (NDUFS4, NDUFA12L, NDUFA8 and C20ORF7). DNA sam-
ples of parents of patient P5 were not available.
Patient P3 carried a known homozygous deletion c.291delG
(p.Trp97X) in exon 3 [27]. Her parents were heterozygous for the mu-
tation. Patient P4 presented the c.291delG deletion inherited from the
father (p.Trp97X) in exon 3 and the c.472_476dupAAGTC duplication
inherited from the mother (p.Tyr160SerfsX31) in exon 5 (Fig. 2C). Pa-
tient P7 presented with the c.355G>C substitution inherited from his
father (p.Asp119His) in exon 4 and the c.462delA deletion inherited
from his mother (p.Lys154AsnfsX35) in exon 5. The 2 novel muta-
tions c.178_528del (P1) and c.472_476dupAAGTC (P4) were not de-
scribed in SNP databases.
Prenatal diagnostic (PND) using haplotyping at the locus and di-
rect sequencing of the NDUFS4 gene was performed for ﬁve of these
families (Fig. 2).
3.4. Founder mutations
Based on the origins of our NDUFS4 families, founder effects in the
North African population and in the Ashkenazi Jewish population
were hypothesized. The affected children carrying the same mutation
were expected to be homozygous by descent for the polymorphic
markers (SNPs and microsatellites) ﬂanking the NDUFS4 gene on
chromosome 5 (Table 2) whereas their parents were heterozygous
for the markers at this locus (data not shown).
The Moroccan patients P2, P5 and P6 carrying the c.99-1G>A mu-
tation shared an identical haplotype for 14 markers over an 11.5 Mb
region of chromosome 5 that spanned the NDUFS4 locus (D5S2082
to D5S1968). The Algerian patient P3 and the Moroccan patient P4
carrying the c.291delG mutation shared an identical haplotype for 5
markers over a 1.9 Mb region of chromosome 5 that spanned the
NDUFS4 locus (D5S623 to D5S2076). The c.462delA mutation has
been previously reported in 2 Ashkenazi Jewish patients [23,28]. For
this mutation, we identiﬁed an haplotype on the maternal allele of
patient P7 that could be tested for the other patient from Ashkenazi
Jewish population carrying the same mutation if DNA sample can be
obtained [28].
4. Discussion
Genotype–phenotype correlations are poor in patients with Leigh
syndrome. Clinical signs such as hypotonia, psychomotor retardation
or regression, vision impairment or apnea are not speciﬁc and may be
observed in any patients with Leigh syndrome. During the last four
years, we analyzed RC assembly with BN-PAGE in ﬁbroblasts of pa-
tients with CI deﬁciency. This study allowed us to identify a constant
abnormal BN-PAGE proﬁle in NDUFS4 patients (Fig. 1). We conﬁrmed
here in all NDUFS4 patient ﬁbroblasts the results of previous reports
describing the accumulation of the 830 kDa sub complex with a
total absence of the fully assembled holo-enzyme-CI in a few
NDUFS4 patients and NDUFS4 KO mice [10,14,15,17] (Table 3).Mutations in NDUFV1 and NDUFS6 lead also to the accumulation of
the 830 kDa sub complex but in presence of fully assembled CI
[15,16].
To date, 13 patients from 10 families with NDUFS4mutations were
previously described [7,22,23,27–32]. We studied here the clinical,
biochemical, radiologic and genetic features of ﬁve new NDUFS4 pa-
tients and compared them to the phenotype of all other reported
NDUFS4 patients (Table 1). We observed common clinical and biolog-
ical features including early onset (5 days–22 months, mean
4.5 months) and permanent signs such as hypotonia (18/18 patients,
100%), vision impairment (absence of eye contact in 8/8 patients or
nystagmus/ptosis/strabism/ophthalmoplegia in 7/7), failure to thrive
(7/7), feeding problems (7/7) and pyramidal syndrome (4/4). Fre-
quent signs included apnoeic episodes, bradypnea or cyanosis (10/
12, 83%), psychomotor retardation or regression (9/12, 75%), abnor-
mal EEG (6/9, 67%) with epilepsy or seizures (4/7, 57%), depressed
tendon reﬂexes (3/5, 60%), hepatomegaly (4/7, 57%), post-natal
growth retardation (6/12, 50%) and hypertrophic cardiomyopathy
(5/11, 45%). Intra-uterine growth retardation (IUGR) was occasional-
ly observed (6/14, 43%) with birth of 4 premature babies. Vomiting
was occasionally observed (2/7, 29%). Muscle impairment (atrophy,
rhabdomyolysis, or abnormal EMG), liver impairment (cytolysis or
cholestasis), renal functions impairment, peripheral neuropathy, ane-
mia, hyperkinesia/dystonia/athetoid movements and deafness/
sensorineural hearing loss were never described in these patients. Pa-
tients have a short life expectancy, from 3 months to 27.5months of
life (mean 9.3 months) and death was always triggered by cardio res
piratory failure (8/8, 100%).
Abnormal brain images (CT-Scan/MRI) were observed in all pa-
tients (15/15, 100%). We recently report a common pattern of brain
MRI imaging in patients with mitochondrial diseases and CI deﬁcien-
cy [26]. Bilateral and symmetric brainstem lesions were consistent
features in this deﬁciency. In this study, almost all NDUFS4 patients
presented with brainstem and basal ganglia signal abnormalities or
involvement (11/12, 92% and 9/12, 75%, respectively). Cortical atro-
phy was occasionally observed (3/12, 25%). Conﬁrming our previous
report, cerebellar atrophy, corpus callosum anomaly, supra-tentorial
stroke-like lesions, necrotizing leukoencephalopathy or calciﬁcations
were never reported in NDUFS4 patients [26].
Muscle histology with non speciﬁc lipids accumulation was fre-
quent (4/5, 80%). Ragged red ﬁbers were described in one patient
(1/7, 14%). Lactate elevation in plasma and in CSF was very frequently
observed (15/16, 94% and 11/12, 92% respectively).
Finally, RC was considered as deﬁcient when residual activity of a
complex was fewer than 80%. CI deﬁciency was constant in muscle in
all patients (15/15, 100%) with a residual activity of 3 to 54% (mean
24.5%) of the control values. CI deﬁciency in skin ﬁbroblasts was fre-
quent (10/11 patients, 91%) but milder than in muscle with a residual
activity of 15 to 85% (mean 45%) of the control values. CIII deﬁciency
was reported in muscle and skin ﬁbroblasts in one patient (1/10, 10%
and 1/11, 9%, respectively): CIII residual activity ranged from 57 to
197% of (mean 105%) in muscle and from 67 to 160% of residual activ-
ity (mean 108%) in ﬁbroblasts. We did not observe correlation be-
tween CI residual activities in muscle and/or ﬁbroblasts and
phenotype severity and/or age of onset.
There was a discrepancy between the residual CI enzyme activity
measured by the spectrophotometric assays and the absence of fully
assembled CI in BN-PAGE in NDUFS4 patient ﬁbroblasts. Explanation
for this discrepancy between the BN-PAGE ﬁndings and the spectro-
photometric assay was recently given [10]. In the NDUFS4 KO mouse
sample, mild extraction conditions allowed detection of active fully
assembled CI, but only in association with CIII, in various supercom-
plex forms (CI+CIII2 and CI+CIII2+CIV). This ﬁnding provided evi-
dence that CIII helps CI stabilization. NDUFS4 KO mice data suggested
that the NADH dehydrogenase module can attach to the 830 kDa sub-
complex to give fully assembled CI, thus NADH dehydrogenase
Fig. 1. BN-PAGE analysis of mitochondria from six NDUFS4 patients (P) and from control (C) using antibodies against GRIM19 for complex I (CI), SDHA (70 kDa) for complex II (CII),
core 2 for complex III (CIII), COXI for complex IV (CIV) and F1 beta subunit for complex V (CV).
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supercomplex containing CIII [10]. In our study, we used extraction
conditions allowing the detection of supercomplexes like CIII2+CIV
but not CI+CIII2 or CI+CIII2+CIV. Milder extraction conditions,Fig. 2. (A) Pedigree of the sevenNDUFS4 families included in this study. The stars indicate subje
parative genomic hybridization (CGH) proﬁles of chromosome 5q11.2 region using high resol
with each point representing an individual oligonucleotide probe. The deletedDNA segment is i
by the C-OZSCY and C-OZSEN probes. The deleted region includedNDUFS4 exons 3 to 5. Base po
(C) Identiﬁcation of the c.472_476dupAAGTC mutation in patient P4.likely representing a more physiological situation, could be useful to
allow these loose interactions to remain intact.
All the NDUFS4 mutations happened on conserved amino-acids.
Except the c.355G>C mutation (p.Asp119His), they all result in acts that have been tested. PND prenatal diagnosis.(B–C) NewNDUFS4mutations (B) Com-
ution oligonucleotides microarray (Affymetrix Cytogenetics Whole-Genome 2.7M array),
ndicated. Patient P1 harbors a large deletion encompassing a 65 to 88Mb sequenceﬂanked
sition according to UCSCGenomeBrowser on Human Feb. 2009 (GRCh37/hg19) assembly.
Table 2
Genotypes of patients carrying the c.99-1G>A mutation (P2/P5/P7), the c.291delG mutation (P3/P4) and the c.462delA mutation (P7 and his mother) at the NDUFS4 locus.
Mutation c.99-1G>A c.291delG c.462delA
Genetic
markers
Position (bp) on
chromosome 5
Patient P2
(Morocco)
Patient P5
(Morocco)
Patient P6
(Morocco)
Patient P3
(Algeria)
Patient P4 (Morocco) Patient P7
(Israel)
Mother of
patient P7
D5S634 41283932–41284079 184190 188188 186186 nd nd nd nd
D5S2082 42009428–42009627 195201 195201 195195 nd nd nd nd
D5S665 42316853–42317003 146146 146146 146146 nd nd nd nd
D5S1958 43046960–43047194 242-234 242-242 242-242 nd nd nd nd
D5S2087 44215771–44216022 247-245 247-247 247-247 nd nd nd nd
D5S2063 44259084–44259309 218-220 218-218 218-218 nd nd nd nd
D5S2086 45567923–45568072 145-143 145-145 145-145 nd nd nd nd
D5S466 50272950–50273103 288-290 288-288 288-288 nd nd nd nd
D5S822 50511135–50511370 246-238 246-246 246-246 nd nd nd nd
D5S660 50801765–50801913 258-250 258-258 258-258 nd nd nd nd
D5S2092 52035553–52035660 171-171 171-171 171-171 175-175 173-181 171-173 171-171
D5S623 52285603–52285700 140-140 140-140 140-140 154-154 154-148 146-140 146-154
D5S2037 52612556–52612829 275-275 275-275 275-275 275-275 275-279 283-277 283-283
NDUFS4 mutations c.99-1G>A/c.99-
1G>A
c.99-1G>A/c.99-
1G>A
c.99-1G>A/c.99-
1G>A
c.291delG/
c.291delG
c.291delG/
c.472_476dupAAGTC
c.462delA/
c.355G>C
c.462delA / -
D5S1969 53242847–53243107 256-254 256-258 256-254 256-256 256-260 258-256 258-248
D5S1968 53542570–53542789 207-215 207-207 207-207 207-207 207-215 215-207 215-207
D5S2076 54206863–54206965 107-107 107-107 115-115 105-105 105-99 119-119 119-109
D5S664 54973707–54973827 116-116 116-114 128-128 120-120 128-134 nd nd
D5S645 55305899–55306005 177-179 163-163 173-173 nd nd nd nd
D5S2068 55624221–55624467 244-246 246-248 238-238 nd nd nd nd
D5S407 55994758–55994904 116-118 108-108 118-118 nd nd nd nd
D5S2107 58149851–58150024 177-177 183-183 177-177 nd nd nd nd
Loci are listed according to their relative chromosomal position from 5p13.1 to 5q11.2 (top to bottom) according to Ensembl (GRCh37). Bold indicates common haplotypes.
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sensus site (AA 171–173) to disappear (Table 3). This diminution of
phosphorylation may result in a marked reduction of the NADH–
ubiquinone oxidoreductase activity which does not respond any lon-
ger to cAMP activation [19]. All the NDUFS4 mutations, including a
missense mutation (c.355G>C, p.Asp119His), result in defective as-
sembly of CI, as conﬁrmed by the abnormal BN-PAGE proﬁle with a
complete loss of the fully assembled CI (~1 MDa) and theTable 3
Summary of NDUFS4 mutations.
Patients
described
in this
study
NDUFS4 mutation
(NM_002495.2)
AA change Truncated
protein
Founder mutation
(this study)
c.44G>A p.Trp15X +
P2, P5, P6 c.99-1G>A p.Ser34IlefsX5
(skipping of exon 2)
+ in Moroccan
population
P1 c.178_528del p.Asp60_Lys175del
(loss of exons 3 to
5)
+
c.202_203delCCinsG p.Pro68GlufsX5 +
c.221delC p.Thr74IlefsX18 +
P3, P4 c.291delG p.Trp97X + in North African
population
c.316C>T p.Arg106X +
c.351-2A>G unknown +
P7 c.355G>C p.Asp119His -
P7 c.462delA p.Lys154AsnfsX35 + probably in
Ashkenasi Jewish
population
c.466_470dupAAGTC p.Lys158SerfsX33 +
P4 c.472_476dupAAGTC p.Tyr160SerfsX31 +accumulation of the late stage assembly intermediate of ~830 kDa,
as observed in all NDUFS4 patients that have been tested (Table 3).
5. Conclusions
In summary, we report here BN-PAGE as an efﬁcient diagnostic
approach to rapidly identify NDUFS4mutations in patients with CI de-
ﬁciency. NDUFS4 mutations result in fatal early onset mitochondrialLoss of cAMP-
dependent pro-
tein kinase A
phosphorylation
consensus site
(RVSTK, AA
171-175)
Abnormal
BN-PAGE
proﬁle with
accumulation
of the late
stage assem-
bly interme-
diate of ~830
KDa
References
Mutations BN-PAGE
+ + Petruzzella et al. [30] Antonicka et al.
[11], Iuso et al.
[32]
+ + Benit et al. [22] and Calvo et
al. [7]
This study
+ + This study This study
+ + Visch et al. [34] Vogel et al. [17]
+ nd Calvo et al. [7] nd
+ + Budde et al. [27] Antonicka et al.
[11]
+ + Budde et al. [27], Budde et al.
[31],
Ulgade et al.
2004, Vogel [17]
+ nd Calvo et al. [7] Nd
- + Leshinsky-Silver et al. [23] Leshinsky-Silver
et al. [23]
+ + Anderson et al. [28],
Leshinsky-Silver et al. [23],
Calvo et al. [7]
This study
+ + van den Heuvel et al. [29] Antonicka et al.
[11], Vogel et al.
[17]
+ + This study This study
1069Z. Assouline et al. / Biochimica et Biophysica Acta 1822 (2012) 1062–1069disease with typical brain images, i.e. the association of brainstem and
basal ganglia signal abnormalities. A clear pattern of clinical symptoms
was not identiﬁed for NDUFS4 patients. However, a characteristic
BN-PAGE proﬁle with a complete loss of the fully assembled CI
(~1 MDa) and the accumulation of the late stage assembly intermediate
of ~830 kDawas observed in allNDUFS4 patients, suggesting that a pre-
screening of patients for NDUFS4 sequencing based on BN-PAGE proﬁle
is useful.
This report enlarges the phenotypic spectrum of NDUFS4mutations
and suggests that brainMRI images (brainstemand basal ganglia anom-
alies) associatedwith a characteristic BN-PAGE proﬁle (accumulation of
the 830 KDa assembly intermediate) in patients with early-onset Leigh
syndromemay orientate to NDUFS4 gene screening. In addition, we de-
scribe here the ﬁrst NDUFS4 founder mutations (c.99-1G>A and
c.291delG) in the North African population.
In conclusion, we suggest that patients with Leigh syndrome and
complex I deﬁciency should ﬁrst prompt to exclude mtDNA involve-
ment and investigate RC assembly with BN-PAGE. This strategy may
help focusing on speciﬁc genes and contribute to faster mutations
identiﬁcation in complex I deﬁciency.
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